Very happy to share our study published Journal of Clinical Oncology ! ascopubs.org/doi/full/10.12…

➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4…

#APCCC24 Advanced Prostate Cancer Consensus Conference What is the role of digital rectal exam (DRE))👉No role in primary care, no role in early detection by urologist if MRI available, some role in local staging of #ProstateCancer by urologist. Excellent talk by Declan Murphy OncoAlert UroToday.com…

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 outstanding talk by Nick James on triplet vs doublet therapy in mCSPC #ProstateCancer 👉gives shoutout to network meta-analysis by SOUMYAJIT ROY 👉value of triplet unclear in all pts, pts QOL should be considered OncoAlert silke gillessen

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉 #OliverSartor 👉is there any role of total therapy 👇 in synchronous low volume mCSPC #ProstateCancer 👉no data showing value of MDT or superiority of triplet over ADT+ ARPI👇Summary👉pts’s wishes should drive aggressive Rx OncoAlert silke gillessen

#APCCC2024 Advanced Prostate Cancer Consensus Conference 👉Multiple prognostic markers have emerged in mCSPC #ProstateCancer but predictive markers lacking👉emerging role of Decipher and gene signatures by AttardLab (just published) Nick James 👇OncoAlert silke gillessen PCF Science Irbaz Riaz MD,MS,MBI,PhD

#APCCC24 Advanced Prostate Cancer Consensus Conference very insightful talk by the master Alberto Briganti on the role of surgery in high risk #ProstateCancer cancer 👉compelling argument for role of surgery until randomized trial shows inferiority of surgery vs radiation OncoAlert UroToday.com Amer. Urol. Assn.

Just in BMC 👉Full protocol of our recently initiated, National Cancer Institute RO1 funded, randomized trial of creatine supplementation + Resistance training in advanced #ProstateCancer undergoing ADT Adriana M Coletta, PhD, MS, RD Neli Ulrich, PhD OncoAlert PCF Science Huntsman Cancer Institute UroToday.com

Very honored to receive the Conquer Cancer, the ASCO Foundation merit award #ASCO24 ! Despite challenges, it’s been a rewarding year. Grateful for my amazing support system, incredible team at GU Cancer Research Program @HuntsmanCancer Huntsman Cancer Institute, and great mentorship of Neeraj Agarwal, MD, FASCO! See you all at #ASCO24 !

Just in ACS Journal Cancer 👉Pts w/ clear cell mRCC #kidneycancer from real world Flatiron database s/p ICI Rx👉 Similar survival w/ cabo + ICI vs. cabo monoRx aligning w/ #CONTACT03 trial results UroToday.com OncoAlert @huntsmangu Umang Swami Neeraj Agarwal, MD, FASCO 👇tinyurl.com/2w79fbt8

Just in 👉data from SWOG Cancer Research Network 1216 trial in mHSPC#prostatecancer👉 PSA level at 3 and 7 months after starting ADT Rx are strongly prognostic of OS: It’s time to design de- or escalation trials based on response biomarkers. OPEN access👉 tinyurl.com/3azhpt4r OncoAlert UroToday.com

Just in 👉A comprehensive review of PARPi+ARPI combos in 1st line mCRPC #ProstateCancer 👇 by Rana McKay Alicia Morgans, MD, MPH neal shore et al. OPEN access link👉 tinyurl.com/4kajr2h3 OncoAlert UroToday.com PCF Science

Great hosting Neeraj Agarwal, MD, FASCO back to Internal Medicine at Iowa grand-round, where he started his journey as a resident. Elegant talk. Nice to see familiar faces being acknowledged
Umang Swami Benjamin L Maughan Nicolas Sayegh, MD Georges Gebrael Chadi Hage Chehade Sumanta K. Pal, MD, FASCO Petros Grivas Nishita Tripathi, MD #SumatiGupta

Just in Eur Urol Focus 👉🏻Pts w/ synchronous (Dx-Mx ≤ 3 mos) vs metachronous mRCC #kidneycancer treated w/ 1st line ICI Rx ➡️worse clinical outcomes 👇🏻
tinyurl.com/kheb6542 Georges Gebrael Luis A. Meza Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer Genitourinary Cancer Research Team @CityofHope UroToday.com OncoAlert

Clémentine Le Magnen outlines nicely the opportunities / challenges of #PatientDerivedOrganoid development in #ProstateCancer

•Amazing opportunities for personalised decision-making
•Issues around #TME & maintenence of patient derived characteristics

#EAU24

#ProstateCancer Study:
🧬PTEN loss linked to worse survival in mCRPC patients. This genetic test could help identify high-risk patients for tailored treatment strategies.
#Urology #Oncology
Shilpa Gupta OncoAlert ASCO Prostate Cancer Foundation Advanced Prostate Cancer Consensus Conference
doi.org/10.1200/PO.23.…

New data from EV302 Enfortumab Vedotin & pembrolizumab for upper tract disease (~25% of pts). UTUC has distinct biological features including more FGFR alterations. PFS & OS HR of 0.50 & 0.53 respectively in the subset is in line with the whole population (0.45 and 0.47) #EAU24

I’m honored to be entrusted with this important work and thrilled to be part of such a stellar leadership team Huntsman Cancer Institute! 🙏🏽🎊 University of Utah Radiation Oncology Neli Ulrich, PhD Theresa Werner MD Neeraj Agarwal, MD, FASCO

U.S. FDA FDA Oncology Pooled Analysis:
Jaleh Fallah, MD et al.
🧬This FDA analysis suggests PARPi drugs for prostate cancer work best for mutations in BRCA1, BRCA2, CDK12 & PALB2 genes.

ASCO Journal of Clinical Oncology OncoAlert Advanced Prostate Cancer Consensus Conference Prostate Cancer Foundation Toni Choueiri, MD Timil Patel, MD Jennifer Gao…

Congrats Georges Gebrael for this amazing news of your IM residency match with University of Utah Department of Internal Medicine Very well deserved. We are very happy to continue to work with a superstar like you.

Unreal feeling! I am honored to match University of Utah Department of Internal Medicine Wouldn't be possible without the tremendous support from my family, friends, colleagues & specially my mentors and team who believed in me Neeraj Agarwal, MD, FASCO Umang Swami Benjamin L Maughan Sumanta K. Pal, MD, FASCO Excited for what's ahead #Match2024